SU-11739

SU-11739
Clinical data
Other names	AGN-1133; J-508; N-Methyl-N-propargyl-1-aminoindane; (±)-N-Methylrasagiline; (RS)-N-Methylrasagiline
Identifiers
	IUPAC name N-methyl-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine;
CAS Number	1875-49-6;
PubChem CID	15179;
ChemSpider	14447;
UNII	37N2TO074R;
CompTox Dashboard (EPA)	DTXSID40953900 ;
Chemical and physical data
Formula	C13H15N
Molar mass	185.270 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(CC#C)C1CCC2=CC=CC=C12;
	InChI InChI=1S/C13H15N/c1-3-10-14(2)13-9-8-11-6-4-5-7-12(11)13/h1,4-7,13H,8-10H2,2H3; Key:CSVGVHNFFZWQJU-UHFFFAOYSA-N;

SU-11739 (other developmental code names AGN-1133, J-508; also known as N-methyl-N-propargyl-1-aminoindane) is an experimental monoamine oxidase inhibitor (MAOI) that was never marketed.

It is a dual or non-selective irreversible monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) inhibitor, with preference for inhibition of MAO-B over MAO-A. It is less selective for MAO-B inhibition than AGN-1135 (racemic rasagiline) or rasagiline. In addition to its MAOI activity, SU-11739 has been reported to have strong activity as a catecholamine releasing agent. Similarly to rasagiline, but unlike selegiline and desmethylselegiline, SU-11739 is not a monoaminergic activity enhancer (MAE).

The drug is the racemic N-methylated analogue of rasagiline. It is also a ring-cyclized analogue of pargyline with about 20 times the MAOI potency of pargyline.

SU-11739 was discovered before rasagiline and was patented in 1965.